Show simple item record

dc.contributor.authorYang, Lingjian
dc.contributor.authorWest, Catharine M L
dc.date.accessioned2018-04-15T17:08:58Z
dc.date.available2018-04-15T17:08:58Z
dc.date.issued2018-03-20
dc.identifier.citationHypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy. 2018, Br J Radiolen
dc.identifier.issn1748-880X
dc.identifier.pmid29513038
dc.identifier.doi10.1259/bjr.20180036
dc.identifier.urihttp://hdl.handle.net/10541/620883
dc.description.abstractHypoxia is a generic micro-environmental factor of solid tumours. High levels of hypoxia lead to resistance to radiotherapy, which can be targeted by adding hypoxia-modifying therapy to improve clinical outcomes. Not all patients benefit from hypoxia-modifying therapy, and there is a need for biomarkers to enable progression to biologically personalised radiotherapy. Gene expression signatures are a relatively new category of biomarkers that can reflect tumour hypoxia. This article reviews the published hypoxia gene signatures, summarising their development and validation. The challenges of gene signature derivation and development, and advantages and disadvantages in comparison with other hypoxia biomarkers are also discussed. Current evidence supports investment in gene signatures as a promising hypoxia biomarker approach for clinical utility.
dc.language.isoenen
dc.rightsArchived with thanks to The British journal of radiologyen
dc.titleHypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy.en
dc.typeArticleen
dc.contributor.departmentTranslational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital NHS Foundation Trust , Manchester , UKen
dc.identifier.journalThe British Journal of Radiologyen
html.description.abstractHypoxia is a generic micro-environmental factor of solid tumours. High levels of hypoxia lead to resistance to radiotherapy, which can be targeted by adding hypoxia-modifying therapy to improve clinical outcomes. Not all patients benefit from hypoxia-modifying therapy, and there is a need for biomarkers to enable progression to biologically personalised radiotherapy. Gene expression signatures are a relatively new category of biomarkers that can reflect tumour hypoxia. This article reviews the published hypoxia gene signatures, summarising their development and validation. The challenges of gene signature derivation and development, and advantages and disadvantages in comparison with other hypoxia biomarkers are also discussed. Current evidence supports investment in gene signatures as a promising hypoxia biomarker approach for clinical utility.


This item appears in the following Collection(s)

Show simple item record